Introduction {#sec1-1759091419845524}
============

Biomarkers play a pivotal role in the clinical diagnosis of neurodegenerative disorders in particular for Alzheimer's disease (AD). AD biomarkers reflect the typical neuropathological hallmarks: hyperphosphorylated tangles and amyloid plaques. While increased phosphorylated tau (p181Tau) and total tau (tTau) indicate the tangle pathology in cerebrospinal fluid (CSF), amyloid-beta (Aβ) 1-42 (Aβ~42~) levels and especially the decreased Aβ~42~ to amyloid-β 1-40 (Aβ~40~) ratio (Aβ~42/40~) embody the cerebral amyloid pathology that can be verified postmortem. The importance of these biomarkers in the clinical diagnosis of AD has been reflected in national (e.g., German) and international guidelines and recommendations ([@bibr6-1759091419845524]; McKhann et al., 2011; [@bibr4-1759091419845524]; [@bibr5-1759091419845524]). Novel research guidelines even more emphasize the significance of these biomarkers ([@bibr9-1759091419845524]).

We have recently shown that CSF biomarkers measured in different clinically validated and certified laboratories are interpreted discordantly in up to 31.5% of cases for Aβ~42~ ([@bibr17-1759091419845524]), whereas Aβ~42/40~ seems to be less prone to pre-analytical factors ([@bibr7-1759091419845524]). It is not clear whether these findings are caused by pre-analytical or analytical interferences.

Apolipoprotein E (*APOE*) ε4 is the most prominent genetic risk factor for late-onset AD ([@bibr1-1759091419845524]). Several studies have shown that *APOE* ε4 is highly associated with amyloid pathology at any cognitive stage of AD ([@bibr10-1759091419845524]).

We aimed to analyze *APOE* ε4 as an interfering factor that leads to inconsistent CSF biomarker results under routine clinical conditions. In addition, this study aims to describe the current difficulties in clinical interpretation of CSF Aβ to make physicians aware of pitfalls. Therefore, CSF samples were sent and analyzed at two different, certified, clinical laboratories for biomarker determination.

Methods {#sec2-1759091419845524}
=======

Study Design {#sec3-1759091419845524}
------------

Within the biomaterial bank of the Department of Psychiatry and Psychotherapy of the University Medical Center Goettingen, we identified 126 samples from patients between 45 and 90 years where AD-relevant CSF biomarkers were measured in two independent, clinically certified laboratories during routine clinical diagnostic procedures, as described recently ([@bibr17-1759091419845524]). CSF biomarkers were measured according to the local standard operating procedures (SOPs), and both laboratories were not informed prior to the study to ensure routine procedures were maintained. No special effort was put in standardizing the SOPs. Biomarkers were measured using commercial and for *in vitro diagnostic* approved enzyme-linked immunosorbent assays (ELISAs). tTau (Fujirebio Cat\# 81572, [RRID:AB_2797379](https://scicrunch.org/resolver/RRID:AB_2797379)) and pTau (Fujirebio Cat\# 81574, [RRID:AB_2797380](https://scicrunch.org/resolver/RRID:AB_2797380)) were measured using ELISAs by Fujirebio (Ghent, Belgium), Aβ~40~ (IBL Cat\# RE59651, [RRID:AB_2797386](https://scicrunch.org/resolver/RRID:AB_2797386)) was measured using ELISAs by IBL International (Hamburg, Germany), and Aβ~42~ (IBL Cat\# RE59661, [RRID:AB_2797387](https://scicrunch.org/resolver/RRID:AB_2797387) and Fujirebio Cat\# 81576, [RRID:AB_2797385](https://scicrunch.org/resolver/RRID:AB_2797385)) was measured using ELISAs by IBL and Fujirebio. CSF biomarkers were interpreted according to the corresponding cutoff values of the respective laboratory. Cutoff values were identified and adjusted during their routine validation procedures. At Center 1, cutoff values were 450 pg/ml for Aβ~42~, 0.05 for the Aβ~42/40~ ratio, 450 pg/ml for tTau, and 61 pg/ml for pTau. At Center 2, cutoff values were 620 pg/ml for Aβ~42~, 0.05 for the Aβ~42/40~ ratio, 320 pg/ml for tTau, and 50 pg/ml for pTau. Cutoff values were not adapted during the study.

A polymerase chain reaction (PCR) was performed to identify the *APOE* genotype and accordance for *APOE* ε4 carriers (E2/E4, E3/E4, and E4/E4) and non *APOE* ε4 carriers (E2/E2, E2/E3, E3/E3) were compared. We compared each CSF biomarker independently and only included data from participants where the CSF biomarkers were significantly above or below cutoff, identified by ±10% of the respective cutoff value (borderline cutoff zone). Concordance was defined as an identical interpretation of biomarkers in both laboratories (either significantly above or below cutoff), whereas discordance was defined as dissimilar biomarker interpretations in the two corresponding laboratories (above the cutoff in one center and below the cutoff in the other center).

Sample Collection {#sec4-1759091419845524}
-----------------

CSF was collected by a lumbar puncture and stored in polypropylene tubes during the clinical diagnostic procedure. The lumbar puncture was performed in a seated position using a traumatic *Quincke needle* (BD Diagnostics, Franklin Lakes, NJ) or an atraumatic *Sprotte cannula* (Pajunk, Geislingen, Germany), according to the preference of the treating physician. The samples were sent immediately to two independent clinical laboratories for CSF biomarker measurements of Aβ~42~, Aβ~40~, Aβ~42/40~, p181Tau, and tTau.

APOE Measurement {#sec5-1759091419845524}
----------------

*APOE* genotyping was performed using a quantitative real-time PCR protocol as described previously ([@bibr2-1759091419845524]), with negative controls for all primer combinations and all PCR reactions run in duplicate. Measurements were carried out using a Stratagene MX3000P Real-Time PCR Cycler (Santa Clara, CA).

Statistics {#sec6-1759091419845524}
----------

Statistical analysis was performed using Prism Graph Pad 8 ([RRID:SCR_002798](https://scicrunch.org/resolver/RRID:SCR_002798)). Age was compared using a student's *t-*test, and cohort differences for discordant CSF biomarkers and gender were analyzed using Fisher's exact test. Correlations were assessed by Spearman correlation and compared after calculating a Fisher *r*-to-*z* transformation.

Study Approval {#sec7-1759091419845524}
--------------

All participants gave their informed consent for biomaterial and data collection prior to inclusion into this study. All data were pseudonymized. The study was approved by the ethics committee of the University Medical Center Goettingen (ethical vote 9/2/16). The study was conducted according to the Declaration of Helsinki.

Results {#sec8-1759091419845524}
=======

Study Cohort {#sec9-1759091419845524}
------------

In this study, 54 (42.9%) participants were *APOE* ε4 carriers with a mean age of 70.4 ± 10.0 years. No *APOE* ε4 allele was found in 72 (57.1%) participants with a mean age of 66.8 ± 10.3 years. There was a trend in distribution for age (*p* = .0502) but not for gender (*p* = .8564) between *APOE* ε4 carriers and noncarriers. CSF biomarker accordance was compared after excluding cases within the borderline cutoff zone (±10%) and age and gender were recalculated for each biomarker. No significant difference in age or gender was observed for any of the analyzed groups ([Table 1](#table1-1759091419845524){ref-type="table"}).

###### 

Analyzed CSF Biomarkers and Corresponding Patients' Data.

![](10.1177_1759091419845524-table1)

                                            CSF Aβ~42~     CSF Aβ~42/40~   CSF tTau       CSF pTau                                                                                                
  ----------------------------------------- -------------- --------------- -------------- -------------- -------------- --------- ------------- ------------- ------- ------------- ------------- -------
  Excluded cases                                                                                                                                                                                  
   Within borderline  cutoff zone  (±10%)   16             14                             12             10                       16            11                    17            14            
  Included cases                                                                                                                                                                                  
   Concordant  (*n*) (%)                    12 (31.6)^a^   46 (79.3)^b^    \<.0001        25 (59.5)^a^   54 (87.1)^b^   .0020     32 (84.2)     57 (93.4)     .1761   35 (94.6)     56 (96.6)     .6414
   Discordant  (*n*) (%)                    26 (68.4)^a^   12 (20.7)^b^    17 (40.5)^a^   8 (12.9)^b^    6 (15.8)       4 (6.8)   2 (5.4)       2 (3.4)                                           
   Age (years)                              68.4 ± 8.6     67.7 ± 9.6      .5693          69.8 ± 10.1    66.6 ± 10.2    .1159     68.2 ± 10.8   66.3 ± 10.0   .3782   70.7 ± 10.7   67.5 ± 10.0   .1536
   Females                                  25             32              .3958          23             35             \>.9999   22            33            .8357   20            30            .0366
   Males                                    13             26              19             27             16             28        17            28                                                

*Note.* Concordant and discordant cases are shown as absolute numbers and percentage. Significance for age differences were analyzed using *t* test, concordance, and gender was analyzed using Fisher's exact test. APOE = apolipoprotein E; CSF = cerebrospinal fluid; Aβ = amyloid-beta; Aβ~42~ = Aβ 1-42; Aβ~42/40~ = Aβ~42~ to Aβ 1-40 ratio; tTau = total tau; p181Tau = phosphorylated 181tau.

Fisher's exact test comparing concordance for Aβ~42~ and Aβ~42/40~ in *APOE* ε4 carriers with *p* = .0147 and non *APOE* ε4 carriers.

*p* = .3285.

CSF Biomarkers {#sec10-1759091419845524}
--------------

Accordance rates were compared for all four validated CSF biomarkers: Aβ~42~, Aβ~42/40~, tTau, and p181Tau. For Aβ~42~, 26 (68.4%) *APOE* ε4 carriers obtained discordant CSF interpretations, whereas only 12 (20.7%) non *APOE* ε4 carriers received a discordant CSF interpretation (*p* \< .0001). Although there were slightly less discordant cases for Aβ~42/40~ than Aβ~42~, there were still significantly more discordant CSF interpretations in *APOE* ε4 carriers (17 participants \[40.5%\]) than noncarriers (8 participants \[12.9%\]; *p* = .0020). We did not observe any differences in the CSF biomarker interpretation of tTau and p181Tau. tTau was discordantly interpreted in six (15.8%) and four (6.8%) cases in *APOE* ε4 and non *APOE* ε4 carriers, respectively (*p* = .1762). Similarly, two (5.4%) *APOE* ε4 carriers and two (3.4%) noncarriers received discordant p181Tau interpretations (*p* = .6414; [Figure 1](#fig1-1759091419845524){ref-type="fig"}; [Table 1](#table1-1759091419845524){ref-type="table"}).

![Presentation of concordant and discordant CSF biomarkers. \*\**p* \< .01. \*\*\*\**p* \< .0001. ns = not significant; APOE = apolipoprotein E; Aβ = amyloid-beta; Aβ~42~ = Aβ 1-42; Aβ~42/40~ = Aβ~42~ to Aβ 1-40 ratio.](10.1177_1759091419845524-fig1){#fig1-1759091419845524}

In *APOE* ε4 carriers, the implementation of Aβ~42/40~ led to a significantly reduced discordancy from 68.4% to 40.5% (*p* = .0147). Comparable discordant rates for Aβ~42~ (20.7%) and Aβ~42/40~ (12.9%) were observed in non *APOE* ε4 carriers (*p* = .3285).

To exclude patients with CSF Aβ concentrations slightly below or above the respective cutoff value, we widened the borderline cutoff zone to ±25%. For Aβ~42~, 12 *APOE* ε4 carriers received discordant interpretations and 7 patients were interpreted concordantly. In *APOE* ε4 noncarriers, only 5 of the 31 participants received discordant biomarker interpretations (*p* = .0004; [Figure 2(a](#fig2-1759091419845524){ref-type="fig"})). Noteworthy, this mismatch was not observed for Aβ~42/40~. Regarding the latter Aβ peptide ratio, only 3 of the 21 *APOE* ε4 carriers and 1 of the 50 non *APOE* ε4 carriers showed discordant results (*p* = .0746; [Figure 2(b](#fig2-1759091419845524){ref-type="fig"})).

![Accordance rate for Aβ~42~ (a) and Aβ~42/40~ (b) after application of a ± 25% borderline zone. \*\*\**p* \< .001. ns = not significant; APOE = apolipoprotein E. Aβ = amyloid-beta; Aβ~42~ = Aβ 1-42; Aβ~42/40~ = Aβ~42~ to Aβ 1-40 ratio.](10.1177_1759091419845524-fig2){#fig2-1759091419845524}

CSF Aβ biomarker concentrations were correlated between Center 1 and Center 2 for *APOE* ε4 carriers and noncarriers separately. Samples with Aβ concentrations above the upper limit of detection were excluded. Aβ~42~ correlated with *r* = .5695 between Center 1 and Center 2 in *APOE* ε4 carriers, whereas the correlation in non *APOE* ε4 carriers was significantly higher *r* = .7541 (*z* = −1.801; *p* = .036; [Figure 3(a) and 3(d)](#fig3-1759091419845524){ref-type="fig"}). The correlations between the two centers for *APOE* ε4 carriers and noncarriers were comparable for Aβ~42/40~ and Aβ~40~. Aβ~42/40~ correlated with *r* = .7886 and *r* = .7173 in *APOE* ε4 carriers and non *APOE* ε4 carriers, respectively (*z* = 0.858; *p* = .195; [Figure 3(b) and 3(e](#fig3-1759091419845524){ref-type="fig"})). For Aβ~40~, a correlation of *r* = .8774 and *r* = .8980 was calculated in *APOE* ε4 carriers noncarriers, respectively (*z* = 0.523; *p* = .300; [Figure 3(c) and 3(f](#fig3-1759091419845524){ref-type="fig"})).

![Correlation of Aβ~42~, Aβ~42/40~, and Aβ~40~ between the two centers for *APOE* ε4 carriers (a to c) and non *APOE* ε4 carriers (d to f). Cases with CSF concentrations above the detection limit were excluded; 53 *APOE* ε4 cases (a to c) and 71 (e and f) or 70 (e) non *APOE* ε4 cases were included. Correlation was significantly lower (*p* = .036) in *APOE* ε4 carriers for Aβ~42~ between the two centers (a and d), whereas similar correlations could be observed for Aβ~42/40~ and Aβ~40~. Concordant CSF biomarkers were defined as consistent CSF levels in both centers above or below the corresponding cutoff values. Areas with concordant cases are colored green, whereas areas with discordant cases are colored orange in Panels (a), (b), (d), and (e). \*Comparison of correlation between *APOE* ε4 carriers and noncarriers for each biomarker after Fisher *r*-to-*z* transformation. APOE = apolipoprotein E; Aβ = amyloid-beta; Aβ~42~ = Aβ 1-42; Aβ~42/40~ = Aβ~42~ to Aβ 1-40 ratio.](10.1177_1759091419845524-fig3){#fig3-1759091419845524}

Aβ~42~, and consequently Aβ~42/40~, but not Aβ~40~, tTau, or p181Tau CSF levels were lower in *APOE* ε4 carriers ([Table 2](#table2-1759091419845524){ref-type="table"}). Aβ~42~ CSF levels were 756.3 ± 295.3 pg/ml for *APOE* ε4 carriers and 1,087.0 ± 411.0 pg/ml for noncarriers at Center 1 (*p* \< .0001) and 604.7 ± 324.9 pg/ml for *APOE* ε4 carriers and 860.0 ± 447.6 pg/ml for noncarriers at Center 2 (*p* = .0006). Aβ~42/40~ CSF levels were 0.0721 ± 0.0363 for *APOE* ε4 carriers and 0.1021 ± 0.0396 for noncarriers at Center 1 (*p \< .0001*) and 0.0473 ± 0.0189 for *APOE* ε4 carriers and 0.0658 ± 0.0176 for noncarriers at Center 2 (*p* \< .0001). Aβ~40~ CSF levels were 11,666 ± 3,747 pg/ml for *APOE* ε4 carriers and 11,586 ± 4,528 pg/ml for noncarriers at Center 1 (*p* = .9160) and 13,726 ± 6,099 pg/ml for *APOE* ε4 carriers and 13,338 ± 6,047 pg/ml for noncarriers at Center 2 (*p* = .7231; [Table 2](#table2-1759091419845524){ref-type="table"}).

###### 

CSF Biomarker Comparison Between *APOE* ε4 Carriers and Noncarriers for Each Center.

![](10.1177_1759091419845524-table2)

                            CSF Aβ~42~       CSF Aβ~42/40~     CSF Aβ~40~        CSF tTau        CSF pTau                                                         
  ------------------------- ---------------- ----------------- ----------------- --------------- ---------------- ------- --------------- ------- --------------- -------
  Center 1                                                                                                                                                        
   *APOE* ε4 carrier        756.3 (295.3)    \<.0001           0.0721 (0.0363)   \<.0001         11,666 (3,747)   .9160   503.6 (325.4)   .0521   71.69 (35.91)   .0452
   Non *APOE* ε4  carrier   1087.0 (411.0)   0.1021 (0.0396)   11,586 (4,528)    392.3 (307.1)   58.68 (35.56)                                                    
  Center 2                                                                                                                                                        
   *APOE* ε4 carrier        604.7 (324.9)    .0006             0.0473 (0.0189)   \<.0001         13,726 (6,099)   .7231   515.1 (370.3)   .0122   67.63 (35.22)   .0645
   Non *APOE* ε4  carrier   860.0 (447.6)    0.0658 (0.0176)   13,338 (6,047)    364.0 (296.2)   56.04 (34.01)                                                    

*Note. APOE* ε4 significantly reduces Aβ~42~ and subsequently Aβ~42/40~ but not Aβ~40~, tTau, or pTau. Due to multiple comparison, *p* values should be considered as α \<.005. APOE = apolipoprotein E; CSF = cerebrospinal fluid; Aβ = amyloid-beta; Aβ~42~ = Aβ 1-42; Aβ~42/40~ = Aβ~42~ to Aβ 1-40 ratio; *SD* = standard deviation; tTau = total tau; p181Tau = phosphorylated 181tau.

Discussion {#sec11-1759091419845524}
==========

In this study, we identified *APOE* ε4 as a major factor leading to different Aβ CSF biomarker interpretations in two independent laboratories. However, the *APOE* genotype did not affect Aβ~40,~ tTau, or p181Tau CSF levels.

The ELISAs used for tTau (Fujirebio), p181Tau (Fujirebio), and Aβ~40~ (IBL) were identical in both centers, whereas the ELISAs used for Aβ~42~ were different (IBL and Fujirebio). This could be one reason for a higher discordance in Aβ~42~ compared with Aβ~40,~ tTau, and p181Tau. However, this study reflects the real life in clinical dementia diagnostics, where physicians have limited impact on the used assays but need to rely on the best laboratory praxis in the corresponding centers. Even though it is not unexpected that different immunoassay show less concordance than identical immunoassays, the impact of *APOE* ε4 on the accordance level is surprising. This effect was consistent even after excluding more some samples with CSF biomarkers close to the corresponding cutoff. Despite a substantially broader borderline cutoff zone (±25%), we still observe a significant discordant Aβ~42~ interpretation in *APOE* ε4 carriers compared with *APOE* ε4 noncarriers. This finding indicates that a molecular interaction of *APOE* ε4 with Aβ~42~ or one of the two ELISAs significantly contributes to the observed interlaboratory mismatch for the measurement of Aβ~42~ in CSF. Accordingly, our observation is unlikely explained only by interlaboratory differences in cutoff values.

A further comparison between both immunoassays could improve the diagnostic accuracy in clinical laboratories; however, it is not trivial to determine the exact Aβ levels in CSF and determine whether one immunoassay is superior to the other one.

Different functions of *APOE* have been described within the pathologic pathway of AD (reviewed in [@bibr1-1759091419845524]). Besides assisting the transportation of Aβ through the blood brain barrier, there is strong evidence that *APOE* interacts with Aβ peptides ([@bibr13-1759091419845524]; [@bibr16-1759091419845524]) and promotes conformational changes into β sheets ([@bibr19-1759091419845524]). As described by Strittmatter et al., *APOE* in general ([@bibr14-1759091419845524]), but *APOE* ε4 even faster than *APOE* ε3 ([@bibr15-1759091419845524]), binds to Aβ peptides. This could affect the CSF biomarker measurements using enzyme-based immunoassays. We observed a reduced correlation between the ELISAs by IBL and Fujirebio in *APOE* ε4 carriers compared with noncarriers, supporting the hypothesis that *APOE* ε4 interacts with Aβ~42~ or one of the corresponding ELISAs.

Different studies have compared blood and CSF *APOE* levels. [@bibr18-1759091419845524] reported an age-dependent effect on general *APOE* levels in CSF, whereas the dementia stage (as measured by the clinical dementia rating), the *APOE* genotype, gender, and race did not affect CSF *APOE* levels. Interestingly, CSF but not plasma *APOE* levels showed an *APOE genotype* independent association with Aβ~42~ concentrations in CSF ([@bibr3-1759091419845524]).

According to the study by [@bibr11-1759091419845524], without additional CSF or positron emission tomography (PET) biomarkers, *APOE* has a sensitivity of 65% and specificity of 68% for the detection of AD. Due to the limited diagnostic significance, national and international guidelines do not include *APOE* genotyping in the clinical diagnostics ([@bibr5-1759091419845524]). However, with the knowledge of a significant interference of *APOE* and Aβ biomarker in the CSF, the determination of patients *APOE* genotype should be considered more important.

This study does not intend to explain any causal relation between *APOE* and Aβ but aims to call attention to a critical interpretation of Aβ CSF biomarkers in routine patient care and research. As CSF biomarkers are gaining importance in the etiological diagnosis of dementia, misinterpreted biomarkers have a significant impact on the clinical and therapeutic procedure (e.g., medication). Thus, false-negative CSF biomarker results could lead to insufficient treatment of AD patients.

Novel data suggest higher reproducibility CSF biomarkers using fully automated analyzers (Hansson et al., 2018). However, further validation studies are needed to support the superiority of fully automated analyzers compared with classical ELISAs.

The determination of the *APOE* genotype could be a diagnostic benefit not only as a risk factor for AD but also as an interfering factor for CSF Aβ biomarker measurements, which should be handled and interpreted carefully, in particular in *APOE* ε4 positive patients. Due to the lacking gold standard (post mortem analysis), it is difficult to predict the superiority of one ELISA in this study. However, CSF Aβ concentration slightly above or below the corresponding cutoff value should be questioned even more in *APOE* ε4 positive patients. We recommend additional diagnostic procedures, for example, amyloid-PET if CSF biomarkers and clinical or neuropsychological examinations are conflicting. Moreover, this study strengthens the diagnostic use of Aβ~42/40~ to reduce insecure CSF biomarker interpretations.

Different immunoassays and cutoff points can render discordance between different laboratories. *APOE* ε4 should be taken into account when applying round robin studies to harmonize cutoff values between different centers.

Strengths and Limitations of the Study {#sec12-1759091419845524}
--------------------------------------

The major limitation of this study is the missing of harmonized SOPs, different infrastructures, and immunoassays. However, we did not address these aspects to outline the practical difficulties in the real-life clinical usage of biomarkers. The strength of this study is the naturalistic character of this analysis.

Summary {#sec13-1759091419845524}
=======

CSF biomarker misinterpretations are a widely known problem in clinical practice. This study shows that, besides different immunoassays and cutoff points, the *APOE* status contributes significantly to discordant CSF Aβ biomarkers. *APOE* ε4 increases the risk of misinterpreting CSF Aβ~42~.
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